21 : 13911398 Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L
This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
This can lead to the medication entering the systemic circulation more quickly
Rai PK, Lalramnghinglova H (2011) Ethnomedicinal plants of India with special reference to an Indo-Burma hotspot region: an overview
Muscle is not just about aesthetics
All studies were blinded and placebo-controlled